A5086832799- Phagocytosis and Immune Regulation
- Chronic Myeloid Leukemia Treatments
- Pancreatic and Hepatic Oncology Research
- Chronic Lymphocytic Leukemia Research
- Cancer Mechanisms and Therapy
- Protein Degradation and Inhibitors
- Cancer Research and Treatments
- Neuroendocrine Tumor Research Advances
- Neuroblastoma Research and Treatments
- Cell death mechanisms and regulation
- Nutrition, Genetics, and Disease
University of Wisconsin–Madison
2019-2024
Medical College of Wisconsin
2024
City of Hope
2021
Abstract Purpose: Radiation and cetuximab are therapeutics used in management of head neck squamous cell carcinoma (HNSCC). Despite clinical success with these modalities, development both intrinsic acquired resistance is an emerging problem the this disease. The purpose study was to investigate signaling receptor tyrosine kinase AXL radiation treatment. Experimental Design: To context treatment-resistant HNSCC, we patient-derived xenografts (PDXs) implanted into mice evaluated tumor...
Abstract Background The receptor tyrosine kinase (RTK) epidermal growth factor (EGFR) is overexpressed and an important therapeutic target in Head Neck cancer (HNC). Cetuximab currently the only EGFR-targeting agent approved by FDA for treatment of HNC; however, intrinsic acquired resistance to cetuximab a major problem clinic. Our lab previously reported that AXL leads via activation HER3. In this study, we investigate connection between AXL, HER3, neuregulin1 (NRG1) gene expression with...
Triple-negative breast cancer (TNBC) is characterized by the absence of estrogen receptor, progesterone and receptor tyrosine kinase HER2 expression. Due to limited number FDA-approved targeted therapies for TNBC, there an ongoing need understand molecular underpinnings TNBC development novel combinatorial treatment strategies. This study evaluated role MerTK on proliferation invasion/metastatic potential in TNBC. Immunohistochemical analysis demonstrated expression 58% patient-derived...
Abstract Triple negative breast cancer (TNBC) is characterized by the absence of estrogen, progesterone, and HER2 receptors. It exhibits a higher level aggressiveness compared to other types cancer, with greater likelihood recurrence following standard treatments such as surgery, chemotherapy, radiation. Despite limited FDA-approved targeted therapies for TNBC, there an ongoing need additional molecular targeting agents.Our investigation focused on role receptor tyrosine kinase MerTK its...
Abstract Introduction: The American Cancer Society (ACS) defines dietary supplements as “vitamins and minerals, herbs other botanicals, amino acids, enzymes, more.” ACS advises against supplement use for cancer prevention, with no suggestions survivors. Regardless, 64-81% of survivors 14-32% recently diagnosed patients in the U.S. will begin taking to improve health outcomes. Despite this prevalence, few studies have examined African survivors, that been done include small samples. This...
Abstract Radiation and cetuximab are therapeutics used in the management of head neck squamous cell carcinoma (HNSCC). Despite clinical success with these modalities, development both intrinsic acquired resistance is an emerging problem this disease. Thus, identifying targeting molecules that drive to radiation or essential for improving efficacy treatment approaches. Previously, we identified AXL as a logical molecular target HNSCC indicated it may play pivotal role cetuximab. In our...
<p>Apoptotic bodies in treatment studies</p>
<div>AbstractPurpose:<p>Radiation and cetuximab are therapeutics used in management of head neck squamous cell carcinoma (HNSCC). Despite clinical success with these modalities, development both intrinsic acquired resistance is an emerging problem the this disease. The purpose study was to investigate signaling receptor tyrosine kinase AXL radiation treatment.</p>Experimental Design:<p>To context treatment-resistant HNSCC, we patient-derived xenografts (PDXs)...
<p>Ctx+R428 in HN30-AXL-Y821F</p>
<p>siABL1+R428+Ctx in HN30-AXL WT</p>
<p>Synergy analysis of treatment studies using fractional product method</p>
<p>Clinical characteristics of tumors</p>
<p>Clinical characteristics of tumors</p>
<p>Figure legends to accompany supplemental data</p>
<p>ABL targeting in cetuximab-resistant clones</p>
<p>ABL targeting in cetuximab-resistant clones</p>
<div>AbstractPurpose:<p>Radiation and cetuximab are therapeutics used in management of head neck squamous cell carcinoma (HNSCC). Despite clinical success with these modalities, development both intrinsic acquired resistance is an emerging problem the this disease. The purpose study was to investigate signaling receptor tyrosine kinase AXL radiation treatment.</p>Experimental Design:<p>To context treatment-resistant HNSCC, we patient-derived xenografts (PDXs)...
<p>Ctx+R428 in HN30-AXL-Y821F</p>
<p>Ki67 staining in additional models</p>
<p>Ki67 staining in additional models</p>
<p>siABL1+R428+Ctx in HN30-AXL WT</p>
<p>Synergy analysis of treatment studies using fractional product method</p>
<p>Figure legends to accompany supplemental data</p>
<p>Apoptotic bodies in treatment studies</p>
Abstract Triple negative breast cancer (TNBC) cells lack estrogen, progesterone, and HER2 receptors. TNBC tends to be more aggressive than most types of is likely recur even after surgery treatment. Recently, a few targeted therapies were approved for TNBC, but additional molecular targeting agents are still needed. Previous studies have found that activated MerTK associated with many human cancers, including cancer. In this study, we focused on expression its tumorigenesis immunoregulatory...